Thanks, it works. "dose-dependent and time-dependent" is interesting. It makes it all the more remarkable that in the Phase 1 human trial, some people had apparent positive responses -- given that they were getting very small doses, separated quite a bit in time. (and we know that Kevetrin has a short half-life.)

Hope the company is able to formulate a pill version, as they are currently trying to do, so that people can take it several times a day. If the occasional doses had an effect on some people, there may be dramatic results if the blood level can be kept constant.

It looks like that study did some deep diving into the mechanism of action. That should help with the company's own studies.

By the way, isn't it great that the company didn't have to pay for this study, beyond supplying them with the drug? To me this shows that some scientists are astute enough to recognize the potential, and want to jump on the bandwagon.